Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Therapeutics


[Search within category]


This invention uses sequencing of microbiota community for diagnosis and treatment of lung and nasal dysbiosis.

mTORC2 Specific Inhibitors

UCLA researchers have identified and characterized mTORC2-specific inhibitors useful as a novel treatment of glioblastoma.

Hair Follicle Formation and Hair Growth with Topical BRAF Inhibitors

UCLA Researchers in the Department of Medicine have identified a novel use for topical small molecule BRAF inhibitors to activate hair follicles and drive hair growth.

Predicting, Diagnosing, And Treating Nausea And Vomiting Of Pregnancy And/Or Pregnancy Loss

UCLA researchers have identified genes associated with nausea and vomiting of pregnancy (NVP), which can be used to predict, diagnose and treat NVP and pregnancy loss.

Novel Nanoliposomal Nitroglycerin Formulation for Cardiovascular Therapies

    To address this major limitation, investigators at UCR have developed a nanoliposomal formulation of NTG, which achieves a 70-fold increase in the anti-inflammatory effect of NTG when compared to NTG. This increase in potency allows lower doses to be effective, which could mitigate the common issues seen with high clinical doses of NTG viz. loss of NTG sensitivity and endothelial toxicity. Fig. 1 Adhesion of U937 monocytes to NO-deficient (L-NIO-treated) ECs is significantly blocked by treating ECs with 5 ug/ml nanoliposomal nitroglycerin (NTG-NL). L-NIO is a selective eNOS inhibitor.  Remarkably, this anti-inflammatory dose of NTG in nanoliposomes is 70-fold lower than the dose of free NTG (5uM) required to achieve a similar effect

Preganancy Hormone-Containing Combination Products for the Continuous Treatment of Autoimmune Diseases

UCLA researchers in the Departments of Neurology have discovered that the combination of certain pregnancy hormones can treat autoimmune disorders like multiple sclerosis.

Modification of Chemical Modification of Nell-1 for Targeting to Musculosketal Tissues

UCLA researchers in the Departments of Plastic Surgery, Dentistry, and Bioengineering, have developed a novel targeted biologic for bone regenerative therapies.

Composition for Bone and Methods of Making and Using the Same

UCLA researchers in the Departments of Plastic Surgery, Bioengineering, and Dentistry have developed a method of controlling the osteoclast/osteoblast ratio for use in osteoporosis therapy.

Chemically Modified Nell-1 and Methods of Making and Using the Same

UCLA researchers have developed ways to chemically modify NELL-1, an osteoinductive factor, that significantly prolong the in vivo circulation time of the protein and retain its osteoblastic activity without any appreciable cytotoxicity.

Use of ApoA-1 to Treat and Prevent Pro-Inflammatory Conditions

UCLA researchers in the Department of Obstetrics and Gynecology have discovered that ApoA-I can be used to treat and prevent pro-inflammatory skin conditions.

Small Molecule Treatment for Androgen Inhibitor-Resistant Cancers

Researchers at the University of California, Davis have developed small molecule inhibitors of androgen receptor variants for the treatment of androgen inhibitor-resistant cancers.

Small Molecules for Melanoma Treatment

Traditional anti-cancer treatments used for metastatic melanoma (skin cancer) can result in cell toxicity, poor efficacy, and low patient survival. UCI researchers have uncovered a class of potent compounds that inhibit cancer cell growth and induce cancer cell death by targeting RhoJ signaling pathways.

Anti-Oxidant Response Modifiers as Treatment for HIV-Associated Neurocognitive Disorder

UCLA researchers have identified anti-oxidative response modulators as a potential treatment for HIV-associated neurocognitive disorders (HAND).

Hair Follicle Stem Cell Activation & Hair Growth by Metabolic Regulators

The Lowry group at UCLA has discovered that topical application of a small molecule accelerates hair growth and combats hair loss by promoting glycolytic metabolism in hair follicle stem cells.

Injectable Novel Therapeutic for Post-Myocardial Infarction Repair

Cardiovascular disease manifested as a myocardial infarction (MI) usually results in the irreversible death of heart muscle cells. While medical treatments can mitigate some symptoms, they often fail to prevent heart failure after a MI. The current standard of care for MI relies on surgical intervention via a coronary artery bypass. An alternative therapeutic approach has been taken in the last few years with the introduction of biomaterials designed to promote neovascularization after an MI and help prevent negative left ventricle remodeling by increasing infarct wall thickness and decreasing volume, fibrosis, and infarct size. 

Bispecific Antibodies for Detection and Treatment of Cancers Associated with EGFR Overexpression

This invention identifies novel bispecific antibodies that can be used to detect and/or treat various cancers that overexpress EGFR family of proteins.

Polyketide Synthase Variants And Uses Thereof

Polyketide synthases are multifunctional enzymes that catalyze the biosynthesis of polyketides. These enzymes make attractive targets because they can be modified to produce commodity chemicals. The invention herein describes methods for producing polyketide synthase variants whose activity and/or substrate specificity can be tailored. An example of a polyketide synthase variant would be 2-pyrone synthase, which produces 2-pyrone. Other modified synthase variants can be generated to produce other key materials including ketides, lactones, etc.

Anti-Microbial Contact Lens With Ocular Drug Delivery

Anti-microbial, anti-fungal drug eluting contact lens for the controlled release of ophthalmic therapeutics.

Antiviral Compounds for HIV and Other Viral Infections

This invention identifies a novel class of HIV inhibitors targeting RNA-protein interactions.

RNA-Based Therapeutic For Mutant KRAS Driven Cancers

Mutations in the KRAS oncogene are found in approximately 20% of human cancers and is the most commonly mutated gene in the RAS family of oncogenes (85% of RAS mutations are KRAS mutations). Moreover, activating KRAS mutations are the major driver mutations in non-small cell lung cancer (NSCLC) with mutations in KRAS accounting for about 30% of NSCLC cases. KRAS mutations are also frequently identified in 40-50% of colorectal cancers (CRC). Despite a long history of research efforts, no targeted therapy is yet available clinically for KRAS mutated cancers.

Chemical Synthesis of Lipid Mediator 22-HDoHE and Structural Analogs

Researchers at the University of California, Davis have developed an efficient method to chemically synthesize the endogenous lipid mediator, 22-hydroxydocosahexaenoic acid (22-HDoHE) which can be applied to related natural mediators and analogs.

Rapid Screening and Identification of Antigenic Components in Tissues and Organs

Researchers at the University of California, Davis have developed an approach to rapidly screen and identify antigenic components in tissues and organs.

Antibodies for Pseudomonas (P.) aeruginosa

Researchers at the University of California, Davis have developed recombinant antibodies (VHH or nanobodies) to diagnose and treat Pseudomonas (P.) aeruginosa infection.

Extracellular Nano-vesicles For Applications In Therapeutic Delivery

Drug delivery relies on nano-sized carriers whose objectives are to protect cargo from the body and to release the cargo at the appropriate site without inducing immunogenic response. The inventors at UCI have developed a method of mass producing extracellular nano-vesicles that have shown promise for drug delivery, but have been slow to progress to clinical trials due to low production yields.

Modulation Of p53 as a Cancer Therapeutic Target

Researchers at the University of California, Davis have designed peptides and oligonucleotide sequences to enhance p53 expression.

  • Go to Page: